 Severe respiratory symptoms related to Covid-19 requiring intensive care (high flow oxygen or invasive measurements)  Patients with pulmonary diseases requiring oxygen supply in medical history  Patients with history of hypersensitivity to Camostat or Niclosamide or to any ingredients to any of the two drugs.  Patients with heart failure (NYHA III or NYHA IV)  Patients with proven malignant tumor  Currently proven influenza infection Pregnancy or breastfeeding History of human immunodeficiency virus 1 or 2 (HIV-1, HIV-2) antibody positive, or tests positive for HIV at screening, acute and chronic infection with hepatitis B or hepatitis C or serologic evidence for active viral hepatitis Immunocompromised patients Creatinine clearance < 60 mL/min AST/ALT > 2xULN Serum potassium > 5.5 mmol/L, platelets < 100.000/ml at Screening Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, whichever is longer, or longer if required by local regulations. Inability or unwillingness to comply with study procedures, including study prohibitions and restrictions. Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g. compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments. Staff member or relative of a staff member, or a subordinate relationship with the Investigator. Vulnerable subject who lives in an institution on court or authority order.

 Severe respiratory symptoms related to Covid-19 requiring intensive care (high flow oxygen or invasive measurements)  Patients with pulmonary diseases requiring oxygen supply in medical history  Patients with history of hypersensitivity to Camostat or Niclosamide or to any ingredients to any of the two drugs.  Patients with heart failure (NYHA III or NYHA IV)  Patients with proven malignant tumor  Currently proven influenza infection Pregnancy or breastfeeding History of human immunodeficiency virus 1 or 2 (HIV-1, HIV-2) antibody positive, or tests positive for HIV at screening, acute and chronic infection with hepatitis B or hepatitis C or serologic evidence for active viral hepatitis Immunocompromised patients Creatinine clearance < 60 mL/min AST/ALT > 2xULN Serum potassium > 5.5 mmol/L, platelets < 100.000/ml at Screening Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, whichever is longer, or longer if required by local regulations. Inability or unwillingness to comply with study procedures, including study prohibitions and restrictions. Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g. compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments. Staff member or relative of a staff member, or a subordinate relationship with the Investigator. Vulnerable subject who lives in an institution on court or authority order.